Antioxidant Treatment of Type 2 Diabetes

This study is currently recruiting participants.

Verified by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), February 2009

First Received: January 23, 2008 Last Updated: February 17, 2009 History of Changes

Sponsored by:	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by:	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier:	NCT00609102

Purpose

This study examines whether an antioxidant taken orally will improve glucose tolerance and insulin secretion in type 2 diabetic subjects.

Condition	Intervention	Phase
Type 2 Diabetes	Drug: Placebo Drug: n-aceylcysteine	Phase 0

MedlinePlus related topics: Antioxidants Diabetes

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind (Subject), Single Group Assignment

Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	90
Study Start Date:	July 2008
Estimated Primary Completion Date:	July 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo: Placebo Comparator	Drug: Placebo one capsule BID
antioxidant drug: Active Comparator n-acetylcysteine	Drug: n-aceylcysteine 450 mgm BID

Eligibility

Criteria

Inclusion Criteria: Subjects with a known diagnosis of type 2 diabetes -

Exclusion Criteria: None, except known intolerance to n-acetylcysteine

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00609102

Contacts

Contact: R Paul Robertson, MD

206-726-1210

Locations

United States, Washington
Pacific Northwest Research Institute	Recruiting
Seattle, Washington, United States, 98122
Contact: R Paul Robertson, MD 206-726-1210 rpr@pnri.org
Principal Investigator: R. Paul Robertson, MD

Sponsors and Collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

More Information

No publications provided

Responsible Party:	Pacific Northwest Research Institute ( R. Paul Robertson )
Study ID Numbers:	Antioxidant trmt type 2, NIH R01 38325-19
Study First Received:	January 23, 2008
Last Updated:	February 17, 2009
ClinicalTrials.gov Identifier:	NCT00609102 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Type 2 diabetes

Study placed in the following topic categories:

Antioxidants
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus

Endocrine System Diseases
Endocrinopathy
Glucose Metabolism Disorders
Metabolic Disorder

Additional relevant MeSH terms:

Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on May 07, 2009